Shruti Chaturvedi

List of Publications by Year
in descending order

77	2,039	279487 23	264894 42
papers	citations	h-index	g-index

77	77	77	3003
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood, 2020, 136, 2080-2089.	0.6	283
2	Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood, 2020, 135, 239-251.	0.6	145
3	Splenectomy for immune thrombocytopenia: down but not out. Blood, 2018, 131, 1172-1182.	0.6	139
4	Evolution of sickle cell disease from a lifeâ€threatening disease of children to a chronic disease of adults: The last 40 years. American Journal of Hematology, 2016, 91, 5-14.	2.0	126
5	Diagnosis and management of the antiphospholipid syndrome. Blood Reviews, 2017, 31, 406-417.	2.8	120
6	Complement in the Pathophysiology of the Antiphospholipid Syndrome. Frontiers in Immunology, 2019, 10, 449.	2.2	87
7	Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis. Blood, 2019, 133, 615-617.	0.6	71
8	Germline mutations in the alternative pathway of complement predispose to HELLP syndrome. JCI Insight, 2018, 3, .	2.3	65
9	Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors. Blood, 2019, 134, 1037-1045.	0.6	58
10	Renal Medullary Carcinoma: Establishing Standards in Practice. Journal of Oncology Practice, 2017, 13, 414-421.	2.5	52
11	Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications. Journal of Thrombosis and Haemostasis, 2021, 19, 607-616.	1.9	45
12	The antiphospholipid syndrome: still an enigma. Hematology American Society of Hematology Education Program, 2015, 2015, 53-60.	0.9	43
13	Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura. Hematology American Society of Hematology Education Program, 2018, 2018, 539-547.	0.9	41
14	Epidemiology and Clinical Manifestations of Immune Thrombocytopenia. Hamostaseologie, 2019, 39, 238-249.	0.9	40
15	Circulating microparticles in patients with antiphospholipid antibodies: Characterization and associations. Thrombosis Research, 2015, 135, 102-108.	0.8	38
16	Rapidly progressive acute chest syndrome in individuals with sickle cell anemia: a distinct acute chest syndrome phenotype. American Journal of Hematology, 2016, 91, 1185-1190.	2.0	38
17	COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria. Blood, 2021, 137, 3670-3673.	0.6	37
18	Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated with Mortality in Patients with Prostate Cancer. PLoS ONE, 2014, 9, e94048.	1.1	36

#	Article	IF	Citations
19	Complement dysregulation is associated with severe COVID-19 illness. Haematologica, 2022, 107, 1095-1105.	1.7	34
20	How targeted therapy disrupts the treatment paradigm for acquired TTP: the risks, benefits, and unknowns. Blood, 2019, 134, 415-420.	0.6	33
21	Post-traumatic stress disorder and depression in survivors of thrombotic thrombocytopenic purpura. Thrombosis Research, 2017, 151, 51-56.	0.8	32
22	Clustering of endâ€organ disease and earlier mortality in adults with sickle cell disease: A retrospectiveâ€prospective cohort study. American Journal of Hematology, 2018, 93, 1153-1160.	2.0	30
23	Management and outcomes for patients with TTP: analysis of 100 cases at a single institution. American Journal of Hematology, 2013, 88, 560-565.	2.0	28
24	Reduced sensitivity of <scp>PLASMIC</scp> and <scp>French</scp> scores for the diagnosis of thrombotic thrombocytopenic purpura in older individuals. Transfusion, 2021, 61, 266-273.	0.8	24
25	Recent advances in the antiphospholipid antibody syndrome. Current Opinion in Hematology, 2014, 21, 371-379.	1.2	22
26	Elevated tricuspid regurgitant jet velocity, reduced forced expiratory volume in 1 second, and mortality in adults with sickle cell disease. American Journal of Hematology, 2017, 92, 125-130.	2.0	22
27	Extracellular Vesicles in the Antiphospholipid Syndrome. Seminars in Thrombosis and Hemostasis, 2018, 44, 493-504.	1.5	22
28	Increased morbidity during longâ€term followâ€up of survivors of thrombotic thrombocytopenic purpura. American Journal of Hematology, 2015, 90, E208.	2.0	21
29	Novel agents in the management of castration resistant prostate cancer. Journal of Carcinogenesis, 2014, 13, 5.	2.5	20
30	Over-testing for heparin induced thrombocytopenia in hospitalized patients. Journal of Thrombosis and Thrombolysis, 2015, 40, 12-16.	1.0	20
31	Cardiovascular disease is a leading cause of mortality among TTP survivors in clinical remission. Blood Advances, 2022, 6, 1264-1270.	2.5	20
32	Thromboelastography Parameters Are Associated with Cirrhosis Severity. Digestive Diseases and Sciences, 2019, 64, 2661-2670.	1.1	19
33	Genome-wide association study to identify variants associated with acute severe vaso-occlusive pain in sickle cell anemia. Blood, 2017, 130, 686-688.	0.6	19
34	Depression and post-traumatic stress disorder in individuals with hereditary hemorrhagic telangiectasia: A cross-sectional survey. Thrombosis Research, 2017, 153, 14-18.	0.8	16
35	Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: case report and systematic review of the literature. Lupus, 2020, 29, 631-639.	0.8	13
36	Counting the cost of caplacizumab. Blood, 2021, 137, 871-872.	0.6	13

#	Article	IF	Citations
37	Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome. Blood Advances, 2021, 5, 1504-1512.	2.5	13
38	Secondary benefit of maintaining normal transcranial Doppler velocities when using hydroxyurea for prevention of severe sickle cell anemia. Pediatric Blood and Cancer, 2017, 64, e26401.	0.8	12
39	How to recognize and manage COVID-19-associated coagulopathy. Hematology American Society of Hematology Education Program, 2021, 2021, 614-620.	0.9	12
40	Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers. Current Rheumatology Reports, 2017, 19, 43.	2.1	11
41	Major adverse cardiovascular events in survivors of immuneâ€mediated thrombotic thrombocytopenic purpura. American Journal of Hematology, 2021, 96, 1587-1594.	2.0	9
42	Eculizumab for refractory thrombosis in antiphospholipid syndrome. Blood Advances, 2022, 6, 1271-1277.	2.5	9
43	Preoperative treatment of anemia and outcomes in surgical Jehovah's Witness patients. American Journal of Hematology, 2019, 94, E55-E58.	2.0	8
44	Characteristics and outcomes of venous thromboembolism in patients with hereditary hemorrhagic telangiectasia. Thrombosis Research, 2018, 169, 41-43.	0.8	7
45	Ex vivo assays to detect complement activation in complementopathies. Clinical Immunology, 2020, 221, 108616.	1.4	7
46	Acral gangrene as a presentation of non-uremic calciphylaxis. Avicenna Journal of Medicine, 2013, 3, 109.	0.3	6
47	Approaches to Bloodless Surgery for Oncology Patients. Hematology/Oncology Clinics of North America, 2019, 33, 857-871.	0.9	6
48	A review of the alternative pathway of complement and its relation to HELLP syndrome: is it time to consider HELLP syndrome a disease of the alternative pathway. Journal of Maternal-Fetal and Neonatal Medicine, 2020, , 1-9.	0.7	6
49	Cardiovascular Disease Is a Leading Cause of Death in Thrombotic Thrombocytopenic Purpura (TTP) Survivors. Blood, 2020, 136, 22-23.	0.6	6
50	Rare Germline Mutations in Complement Regulatory Genes Make the Antiphospholipid Syndrome Catastrophic. Blood, 2019, 134, 4-4.	0.6	6
51	A 15â€year, single institution experience of anticoagulation management in paroxysmal nocturnal hemoglobinuria patients on terminal complement inhibition with history of thromboembolism. American Journal of Hematology, 2022, 97, .	2.0	6
52	Germline ERBB2/HER2 Coding Variants Are Associated with Increased Risk of Myeloproliferative Neoplasms. Cancers, 2021, 13, 3246.	1.7	5
53	Continuous-infusion von Willebrand factor concentrate is effective for the management of acquired von Willebrand disease. Blood Advances, 2021, 5, 2813-2816.	2.5	5
54	Updates on thrombotic thrombocytopenic purpura: Recent developments in pathogenesis, treatment and survivorship. Thrombosis Update, 2021, 5, 100062.	0.4	5

#	Article	IF	Citations
55	Outcomes of Cardiovascular Surgery Utilizing Heparin versus Direct Thrombin Inhibitors in Cardiopulmonary Bypass in Patients with Previously Diagnosed HIT. Thrombosis and Haemostasis, 2020, 120, 300-305.	1.8	4
56	Treatment of chronic immune thrombocytopenia in children with romiplostim. Lancet, The, 2016, 388, 4-6.	6.3	3
57	Blind men and the refractory ITP elephant. Blood, 2016, 128, 1537-1538.	0.6	3
58	Relapsing Thrombotic Thrombocytopenic Purpura (TTP) in a Patient Treated with Infliximab for Chronic Uveitis. Ocular Immunology and Inflammation, 2022, 30, 241-243.	1.0	3
59	Inflammation exerts a nonrandom risk in the acquisition and progression of the MPN: Insights from a Mendelian randomization study. EClinicalMedicine, 2020, 21, 100324.	3.2	2
60	Eculizumab for Refractory Thrombosis in Antiphospholipid Syndrome. Blood, 2020, 136, 10-11.	0.6	2
61	Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian Populations. Blood, 2019, 134, 90-90.	0.6	2
62	Different strokes for older folks (with TTP). Blood, 2019, 134, 2125-2126.	0.6	1
63	Aspirin in ET: will twice a day keep thrombosis away?. Blood, 2020, 136, 151-153.	0.6	1
64	Thirteen Year Retrospective Analysis Of Adult Patients With Autoimmune Hemolytic Anemia At The Cleveland Clinic: Diagnosis and Prevalence Of Associated Disorders. Blood, 2013, 122, 955-955.	0.6	1
65	Thrombotic Thrombocytopenic Purpura At the Cleveland Clinic 2000â€“2012: Review of 100 Cases and Identification of Prognostic Factors. Blood, 2012, 120, 3325-3325.	0.6	1
66	Detectable Or Normal ADAMTS13 Activity In Patients Presenting With Thrombotic Thrombocytopenic Purpura (TTP) Is Associated With Poor Renal Outcomes. Blood, 2013, 122, 4752-4752.	0.6	1
67	Risk Factors for Pregnancy-Associated Venous Thromboembolism: The Role of Maternal Age, Obesity, Smoking and Other Modifiable Risk Factors. Blood, 2018, 132, 3804-3804.	0.6	1
68	Anti-Mullerian Hormone, a Measure of Ovarian Reserve, Is Low in Female Subjects in the Multi-Center Study of Hydroxyurea. Blood, 2019, 134, 890-890.	0.6	1
69	O Complement, Where Aren't Thou. Advances in Chronic Kidney Disease, 2020, 27, 83-85.	0.6	1
70	Abundance of B Cell Receptors Harboring Elongated Polytyrosine and Polyserine Rich Motifs within Their Heavy Chain CDR3 Distinguishes Catastrophic and Antiphospholipid Syndrome. Blood, 2021, 138, 2117-2117.	0.6	1
71	Concurrent Hereditary Hemorrhagic Telangiectasia and Hereditary Hemochromatosis: A Case Report. American Journal of Medicine, 2021, 134, e205-e206.	0.6	0
72	Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer. Blood, 2013, 122, 3626-3626.	0.6	0

#	Article	IF	Citations
73	Thirteen Year Retrospective Analysis Of Adult Patients With Autoimmune Hemolytic Anemia At The Cleveland Clinic: Responses To Therapy. Blood, 2013, 122, 3423-3423.	0.6	0
74	Complement Activation Drives Progression of Pre-Eclampsia to HELLP Syndrome. Blood, 2021, 138, 772-772.	0.6	0
75	Preferences for Accessing Patient Reported Outcomes and Health Information Among Thrombotic Thrombocytopenic Purpura Survivors. Blood, 2021, 138, 3039-3039.	0.6	0
76	Outcomes of a Clinician-Directed Protocol for Discontinuation of Complement Inhibition Therapy in Atypical Hemolytic Uremic Syndrome. Blood, 2020, 136, 24-25.	0.6	0
77	Defects in Sialic Acid Biosynthesis Cause Dysregulation of the Alternative Pathway of Complement. Blood, 2020, 136, 3-3.	0.6	0